Company: BGLC
Filing Date: 2025-05-15
Form Type: 10-Q
Source: 0001477932-25-003821
Chunk: 25

Company: BioNexus Gene Lab Corp
Filing Date: 2025-05-15
Form: 10-Q
Item: Part I, Item 1
Chunk 25
---
 as disclosed in the Consolidated Balance Sheets which are interest-free, unsecured and subject to normal credit terms. 

NOTE 11 - CONCENTRATION OF RISKS a) Major customers For three months ended March 31, 2025, and 2024, respectively, the Company did not have any material recognizable major customers accounted for 10% or more of the Company’s revenue b) Major suppliers For three months ended March 31, 2025, and 2024, respectively, the suppliers who accounted for 10% or more of the Company’s cost of sales and their balances at period ended are presented as follows:   2025  2024  2025  2024  2025  2024   Purchase  Percentage of purchases  Accounts payable trade Vendor A $443,893  $392,225   24.75%  19.45% $507,156  $438,579 Vendor B $324,121  $315,041   18.07%  15.62% $208,379  $215,517 Vendor C $-  $346,329   -   17.17% $-  $318,622   $768,014  $1,053,595   42.82%  52.24% $715,535  $972,718 

 22Table of Contents

BIONEXUS GENE LAB CORP. 

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS 

FOR THE THREE MONTHS ENDED MARCH 31, 2025 AND 2024 

(Currency expressed in United States Dollars (“US$”)) 

(Unaudited)

NOTE 12 – STOCKHOLDERS’ EQUITY As at March 31, 2025 and December 31, 2024, the Company issued and outstanding, common stock is 17,967,663 and 17,967,663 shares respectively.  2023 Reverse Stock Split On June 5, 2023, the Company filed an Article of Amendment to the Articles of Incorporation with the Wyoming Secretary of State to modify the ratio of the Reverse Stock Split from one-for-ten (10) to one-for-twelve (12) (the “Revised Reverse Stock